Glaxosmithkline, LLC
At a glance
Employees500+
In business sinceNot reported
HeadquartersDurham, NC
US patents356
SAM.gov UEIFRHTPHMZMX47
CAGE code667E9
Incorporated inDE
LEI549300Y2PZWSSLJYI255
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
356 US patents granted 2001–2025, 7 of them in the five years to SEP 2025, including 26 design patents.
Pharmaceuticals 252Organic fine chemistry 45Measurement 10Medical technology 7Chemical engineering 5
- (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamideUS RE50497 · granted JUL 22, 2025
- PackageUS D1042109 · granted SEP 17, 2024
- Platelet count-agnostic methods of treating myelofibrosisUS 11,963,962 · granted APR 23, 2024
- Prolyl hydroxylase inhibitorsUS 11,643,397 · granted MAY 9, 2023
- Biopharmaceutical compositions and methods for pediatric patientsUS 11,390,671 · granted JUL 19, 2022
Newest 5 shown · Granted to GlaxoSmithKline LLC · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Glaxosmithkline, LLC | Durham | NC | 500+ | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.